week 2 on tirzepatide Update: Personal Journey Insights Tirzepatide Dosing Chart 2026: 2.5-15

n = 3 per group

Telogen effluvium is considered the most common mechanism

Commenting on the development, Dr Vikas Gupta, Chief Executive Officer, Alkem, said, Semaglutide has the potential to change how we manage metabolic disorders

Lymphedema is a persistent state of edema characterized by the failure of interstitial fluid to return to normal circulation within vessels, resulting in accumulation of fluid and fibro-adipose tissue within extravascular spaces (5)

However, further research is warranted to develop comprehensive, evidence-based guidelines that fully harness this synergy, maximising therapeutic benefits while minimising associated risks